ClinicalTrials.gg
RecruitingNCT07857798Updated Oct 19, 2026

A Study on Associations Between Multidimensional Human Phenotypic Traits and Human Growth and Development

An observational study in Musculoskeletal Growth and Development, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Nanfang Hospital, Southern Medical University · Observational

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This observational study aims to investigate the associations between multidimensional human phenotypic characteristics and growth and developmental features. A total of 500 participants aged 6 to 60 years are planned to be enrolled. Multidimensional phenotypic characteristics will be assessed using non-invasive methods, including fingerprint imaging, foot morphology assessment, facial and tongue feature acquisition, anthropometric measurements, and musculoskeletal examinations. Development-related musculoskeletal characteristics, including plantar arch morphology, lower-limb alignment, joint range of motion, and generalized joint mobility, will also be assessed. The collected data will be analyzed to explore associations between external phenotypic characteristics and musculoskeletal growth and developmental features.

Read the detailed description

Primary Objective:

The primary objective of this study is to investigate the associations between multidimensional human phenotypic characteristics and musculoskeletal growth and developmental features. Multidimensional phenotypic data will be collected using non-invasive assessment methods. Fingerprint characteristics will be obtained using high-resolution fingerprint imaging and characterized according to dermatoglyphic patterns and quantitative features. Foot morphology and plantar arch characteristics will be assessed using three-dimensional foot scanning. Facial and tongue features will be acquired using standardized digital imaging methods. Anthropometric characteristics and joint range of motion will also be measured using standardized procedures.

Musculoskeletal growth and developmental characteristics will be evaluated through physical examination and quantitative measurements. These assessments will include plantar arch morphology, lower-limb alignment, joint range of motion, and generalized joint mobility assessed using the Beighton score. Associations between multidimensional phenotypic characteristics and these musculoskeletal developmental features will be examined using appropriate statistical methods.

Secondary Objective:

The secondary objective is to explore whether combinations of multidimensional phenotypic characteristics are associated with specific patterns of musculoskeletal growth and development. The study will integrate fingerprint, foot, facial and tongue, anthropometric, and musculoskeletal data to investigate potential relationships among different phenotypic dimensions. Exploratory multivariable and machine-learning analyses may be used to identify combinations of phenotypic features associated with musculoskeletal developmental characteristics.

02

Conditions studied

  • Musculoskeletal Growth and Development

Browse trials for

Keywords

  • Human Phenotype
  • Dermatoglyphics
  • Fingerprint Characteristics
  • Foot Morphology
  • Growth and Development
  • Musculoskeletal Development
  • Joint Hypermobility
  • Anthropometry
03

In context

Joint Instability

118 studies on the registry are indexed under Joint Instability; 23 are open to participants now.

This study's planned enrollment of 500 is above the median of 60 across 55 observational studies indexed under Joint Instability.

Browse Joint Instability studies →

Lead sponsor

Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be young adults aged 18 to 25 years recruited primarily from university populations. Eligible participants will undergo standardized assessments of dermatoglyphic, facial, foot, anthropometric, limb proportional, and joint mobility characteristics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to60 years.
  • Able to understand the study procedures and provide .
  • Willing and able to complete the required phenotypic assessments and measurements.

Exclusion criteria

Exclusion Criteria:

  • History of surgery that may affect musculoskeletal morphology or function.
  • Known congenital or developmental disorders that may affect physical growth, limb development, or musculoskeletal morphology.
  • Unable to complete the required study assessments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult Group

    Adult participants aged 18 to 60 years who undergo multidimensional phenotypic assessments, including fingerprint imaging, foot morphology assessment, facial and tongue feature acquisition, anthropometric measurements, joint range of motion assessment, and evaluation of generalized joint mobility and other musculoskeletal developmental characteristics.

    Other: Fingerprint Morphological Characteristics

  • Minor Group

    Participants aged 6 to 17 years who undergo multidimensional phenotypic assessments, including fingerprint imaging, foot morphology assessment, facial and tongue feature acquisition, anthropometric measurements, joint range of motion assessment, and evaluation of generalized joint mobility and other musculoskeletal developmental characteristics.

    Other: Fingerprint Morphological Characteristics

Interventions

  • OtherFingerprint Morphological Characteristics

    Fingerprint images of all ten fingers will be collected using a high-resolution fingerprint scanner. Dermatoglyphic characteristics, including fingerprint pattern types (arch, loop, and whorl), total ridge counts, and ridge counts of individual fingers, will be quantitatively and qualitatively assessed. These naturally occurring phenotypic characteristics are observed and measured only, with no intervention assigned to participants.

06

What researchers measure

Primary outcomes

  1. Foot Arch Morphology Assessed by Arch Index

    Foot arch morphology will be assessed using the Arch Index derived from standardized foot measurements. The Arch Index will be used as a quantitative indicator of plantar arch morphology to characterize variations in foot development among participants.

    Time frame: Baseline

  2. Generalized Joint Hypermobility Assessed by Beighton Score

    Generalized joint hypermobility will be assessed using the 9-point Beighton scoring system. The total score ranges from 0 to 9, with higher scores indicating greater generalized joint hypermobility.

    Time frame: Baseline

Secondary outcomes

  1. Anthropometric and Limb Proportional Measurements

    Anthropometric measurements, including height, body weight, upper- and lower-limb lengths, and other relevant body dimensions, will be collected using standardized measurement procedures. Limb proportional indices will be calculated to characterize individual differences in body and limb morphology.

    Time frame: Baseline

  2. Foot Morphological Characteristics

    Foot morphological characteristics will be assessed using standardized foot scanning and measurement procedures. Measures will include foot dimensions and morphological features derived from plantar and foot-shape data to characterize individual variations in foot morphology.

    Time frame: Baseline

  3. Fingerprint Dermatoglyphic Characteristics

    Fingerprint images will be collected using a standardized acquisition procedure. Dermatoglyphic characteristics, including fingerprint pattern types and other morphological features, will be extracted and analyzed to investigate their associations with foot morphology, limb proportions, and generalized joint hypermobility.

    Time frame: Baseline

  4. Facial Morphological Characteristics

    Standardized facial images will be collected under controlled acquisition conditions. Facial morphological characteristics and quantitative facial features will be extracted from the images to characterize individual variations in facial morphology and to investigate their associations with limb and musculoskeletal phenotypes.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Malek S, Reinhold EJ, Pearce GS. The Beighton Score as a measure of generalised joint hypermobility. Rheumatol Int. 2021 Oct;41(10):1707-1716. doi: 10.1007/s00296-021-04832-4. Epub 2021 Mar 18. PubMed 33738549 ↗
  • Cavanagh PR, Rodgers MM. The arch index: a useful measure from footprints. J Biomech. 1987;20(5):547-51. doi: 10.1016/0021-9290(87)90255-7. PubMed 3611129 ↗
  • Rothhammer F, Llop E, Neel JV. Dermatoglyphic characters and physique: a correlation study. Am J Phys Anthropol. 1982 Jan;57(1):99-101. doi: 10.1002/ajpa.1330570110. PubMed 7137325 ↗
  • Livshits G, Kobyliansky E. Dermatoglyphic traits as possible markers of developmental processes in humans. Am J Med Genet. 1987 Jan;26(1):111-22. doi: 10.1002/ajmg.1320260118. PubMed 3812551 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared at this time due to concerns regarding participant privacy and confidentiality.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 2 updates
  1. Oct 19, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857798
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Chao Chen
Contact
chenchao@smu.edu.cn
86+13580348819

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion